@entity11 ( @entity11 ) contribute to 50% of all central @entity5 in @entity1 and 15% of all @entity11 in adults. @entity2903 ( @entity2904 ) is an oral alkylating agent with activity in high and @entity11 . Various regimens of @entity2904 are currently in use. We attempted to assess the impact of different @entity2904 regimens on the treatment of @entity11 . A systematic review of the literature identified all the studies published in Pubmed, EMBASE and Cochrane databases which met the inclusion criteria. The primary outcome measure was the impact of different @entity2904 regimens on the 12 month progression-free survival (PFS) rates of @entity1 diagnosed with progressive @entity11 . Secondary outcome measures looked at the ability of the three regimens to elicit an objective response and the associated @entity137 . Statistical pooling and calculation of weighted mean average of each proportion (WMAP) was conducted using a random-effects model. 18 studies (736 @entity1 ) were analyzed. PFS at 12 months revealed a WMAP of 0.61 (95% CI 0.44-0.78) for regimen A, 0.59 (0.28-0.89) for regimen B, and 0.91 (95% CI 0.83-0.99) for regimen C (Regimen A--200 mg/m(2)/day for 5 days, repeated every 4 weeks; B--75 mg/m(2)/day for 21 days repeated every 4 weeks; C--75 mg/m(2)/day for 7 weeks with 4 weeks of every 11 weeks). In terms of objective response, WMAP were 0.19 (95% 0.13-0.25), 0.27 (95% CI 0.15-0.39) and 0.21 (95% CI 0.10-0.32) for regimen A, B, C respectively. When analyzing hematological @entity137 , WMAPs were 0.14 (95% 0.11-0.18), 0.35 (0.14-0.56) and 0.23 (95% CI 0.03-0.43). The bulk of evidence originates from the standard 5 day/month regimen A but with a lack of comparative studies. Analysis revealed significant heterogeneity. Although there is possibly an indication that metronomic regimens of @entity2904 result in better PFS and response rate when compared to the conventional standard 5 day regimen, insufficient available data and study heterogeneity preclude any safe conclusions. Well designed randomized controlled clinical trials are needed to establish the efficacy of metronomic regimens of @entity2904 in LGGs.

Using different schedules of @entity2903 to treat low grade XXXX : systematic review of their efficacy and @entity137 .

@entity1 :: ('9606', 'Species') :: ['children', 'patients'] @entity137 :: ('MESH:D064420', 'Disease') :: ['toxicity'] @entity5 :: ('MESH:D009369', 'Disease') :: ['nervous tumors'] @entity11 :: ('MESH:D005910', 'Disease') :: ['Low grade gliomas', 'LGG', 'gliomas'] @entity2903 :: ('MESH:C047246', 'Chemical') :: ['Temozolomide'] @entity2904 :: ('CHEBI:72564', 'Chemical') :: ['TMZ']
@entity11 :: (MESH:D005910,Disease) :: ['gliomas']
